1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Celltrion Pharm Inc

Celltrion Pharm Inc

068760.KS
Celltrion Pharm IncKR flagKorea Exchange
93,500.00
KRW
-600.00
- -

Total Valuation

Celltrion Pharm Inc carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 26.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap- -
Enterprise Value26.67B

Share Statistics

Celltrion Pharm Inc currently has 44.29M shares outstanding.

Shares Outstanding44.29M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

On an enterprise value basis, Celltrion Pharm Inc trades at an EV/EBITDA multiple of 0.46 and an EV/FCF ratio of 0.25. The EV/Sales ratio of 0.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 0.46 provides insight into valuation relative to core operating earnings.

EV / Sales0.05
EV / EBITDA0.46
EV / EBIT0.46
EV / FCF0.25

Financial Position

Celltrion Pharm Inc maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.93, indicating elevated leverage, while an interest coverage ratio of 8.98 demonstrates adequate ability to service its debt obligations.

Current Ratio1.65
Quick Ratio0.46
Debt / Equity36.93
Debt / EBITDA2.76
Interest Coverage8.98

Financial Efficiency

Celltrion Pharm Inc posts a return on equity of 23.76 and a return on invested capital of 7.65.

Return on Equity (ROE)23.76
Return on Assets (ROA)5.57
Return on Invested Capital (ROIC)7.65
Return on Capital Employed (ROCE)13.53
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.35

Taxes

Over the trailing twelve months, Celltrion Pharm Inc has paid 11.81B in income taxes, reflecting an effective tax rate of 22.69.

Income Tax11.81B
Effective Tax Rate22.69

Stock Price Statistics

Celltrion Pharm Inc's stock has declined approximately -1.16279% over the past 52 weeks. The 50-day moving average sits at 55,634.38, while the 200-day moving average is 73,893.09.

Beta (5Y)N/A
52-Week Price Change-1.16279%
50-Day Moving Average55,634.38
200-Day Moving Average73,893.09
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Celltrion Pharm Inc generated 556.00B in revenue and converted that into 40.25B in net income, yielding earnings per share of 908.51. EBITDA reached 58.26B, while operating income came in at 58.26B.

Revenue556.00B
Gross Profit169.68B
Operating Income58.26B
Pretax Income52.06B
Net Income40.25B
EBITDA58.26B
EBIT58.26B
Earnings Per Share (EPS)908.51

Balance Sheet

Celltrion Pharm Inc holds 133.91B in cash and equivalents against 160.58B in total debt, resulting in a net debt position of 85.21B. Total book value stands at 178.23B, with working capital of 188.86B providing operational flexibility.

Cash & Cash Equivalents133.91B
Total Debt160.58B
Net Debt85.21B
Equity (Book Value)178.23B
Book Value Per Share4,023.48
Working Capital188.86B

Cash Flow

Celltrion Pharm Inc produced 77.88B in operating cash flow over the past twelve months. After subtracting -25.47B in capital expenditures, free cash flow totaled 52.41B - equivalent to 1,183.17 per share.

Operating Cash Flow77.88B
Capital Expenditures-25.47B
Free Cash Flow52.41B
FCF Per Share1,183.17

Margins

Celltrion Pharm Inc operates with a gross margin of 30.52, reflecting its pricing power and cost economics. The operating margin of 10.48 and net profit margin of 7.24 provide insight into operational efficiency.

Gross Margin30.52
Operating Margin10.48
Pretax Margin9.36
Profit Margin7.24
EBITDA Margin10.48

Stock Splits

Celltrion Pharm Inc's most recent stock split took place on December 29, 2025 with a 50:51 split ratio.

Last Split Date12/29/2025
Split Ratio50:51

Scores

Celltrion Pharm Inc posts an Altman Z-Score of 1.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.69